Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $167.00 at JPMorgan Chase & Co.

Ascendis Pharma A/S (NASDAQ:ASNDFree Report) had its target price hoisted by JPMorgan Chase & Co. from $165.00 to $167.00 in a research report sent to investors on Wednesday,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock.

A number of other research analysts have also recently weighed in on the company. Stifel Nicolaus lifted their target price on Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a report on Friday, November 15th. UBS Group began coverage on Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a “buy” rating and a $196.00 price objective on the stock. Oppenheimer dropped their target price on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a research report on Friday, November 15th. TD Cowen dropped their price objective on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Finally, StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $191.57.

Get Our Latest Report on Ascendis Pharma A/S

Ascendis Pharma A/S Stock Down 1.4 %

NASDAQ:ASND opened at $127.55 on Wednesday. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $161.00. The firm’s 50 day moving average is $133.53 and its two-hundred day moving average is $133.03. The company has a market cap of $7.74 billion, a P/E ratio of -15.79 and a beta of 0.65.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Westfield Capital Management Co. LP grew its position in shares of Ascendis Pharma A/S by 3.4% during the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock worth $766,523,000 after buying an additional 170,942 shares in the last quarter. Janus Henderson Group PLC boosted its stake in Ascendis Pharma A/S by 6.8% during the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after acquiring an additional 267,881 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Ascendis Pharma A/S by 9.1% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock worth $278,760,000 after acquiring an additional 155,971 shares in the last quarter. Groupama Asset Managment bought a new stake in shares of Ascendis Pharma A/S in the 3rd quarter worth about $60,000. Finally, ARS Investment Partners LLC raised its stake in shares of Ascendis Pharma A/S by 0.9% in the 4th quarter. ARS Investment Partners LLC now owns 265,480 shares of the biotechnology company’s stock valued at $36,549,000 after purchasing an additional 2,369 shares in the last quarter.

About Ascendis Pharma A/S

(Get Free Report)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

Further Reading

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.